Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis - PubMed
5 hours ago
- #TTR amyloidosis
- #pharmacodynamics
- #cardiomyopathy treatment
- Acoramidis showed a greater increase in serum TTR (sTTR) compared to placebo plus tafamidis in the ATTRibute-CM trial after 30 months.
- Acoramidis achieved higher TTR stabilization rates (90.2% vs 60.6% by Western blot) than tafamidis, though sample sizes were small.
- In vitro analysis confirmed acoramidis as a more effective stabilizer across 51 samples representing 17 unique TTR variants.
- The study concludes acoramidis is a near-complete stabilizer for both wild type and variant TTR, but direct comparative clinical trial data are lacking.